Genmab, Pfizer Get European Review of Cervical Cancer Drug
By Colin Kellaher
The European Medicines Agency has validated for review an application from Genmab and Pfizer seeking approval of their tisotumab vedotin antibody-drug conjugate for certain adults with cervical cancer.
Genmab and Pfizer on Friday said the application covers adults with recurrent or metastatic cervical cancer with disease progression on or after systemic therapy.
The companies said a green light would make tisotumab vedotin the first antibody-drug conjugate approved in the European Union for people with cervical cancer.
The U.S. Food and Drug Administration in 2021 granted accelerated approval to tisotumab vedotin, marketed as Tivdak, and last month granted priority review to a request by Genmab and Pfizer to convert the accelerated nod to full approval.
Copenhagen biotechnology company Genmab and New York-based Pfizer are co-developing Tivdak under an agreement in which the companies share costs and profits for the product on a 50-50 basis.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
February 02, 2024 07:29 ET (12:29 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued
-
Utilities: Falling Interest Rates, Growth Outlook Boosting Stocks